China Nuokang Bio-Pharmaceutical Q2 Profit Down - Quick Facts

8/22/2012 6:36 PM ET

China Nuokang Bio-Pharmaceutical Inc. (NKBP: Quote) reported that its second-quarter net income was RMB10.5 million or $1.7 million, down from RMB14.1 million in the prior year period. Net income was RMB0.56 or $0.09 per ADS, compared to RMB0.72 per ADS last year.

Non-GAAP adjusted net income, excluding foreign exchange gains and losses, ESOP-related charges and the ASC 740 adjustment, were RMB11.3 million or $1.8 million, compared to RMB15.7 million in the prior year period.

Revenue for the second quarter of 2012 was RMB72.9 million or $11.5 million, compared to RMB79.5 million in the second quarter of 2011.

Click here to receive FREE breaking news email alerts for China Nuokang Bio-Pharmaceutical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 81 Articles

Editors Pick

Stocks Close Modestly Lower After Lackluster Trading Day - U.S. Commentary

After showing a lack of direction throughout much of the session, stocks ended Monday's trading modestly lower. The slightly lower close on the day partly offset the strength that was seen in the markets last week. The major averages ended the day below the unchanged line but off their lows for the session.

Obama To Deliver Speech On Counterterrorism Policies, Use Of Drones

President Barack Obama reportedly plans to deliver a much-anticipated speech on Thursday outlining his administration's evolving counterterrorism policies. Multiple news sources cited a White House official as saying that Obama will address the use of drones and plans to close the detention facility at Guantanamo Bay in a speech at the National Defense University.

Immigration Officers Union Expresses Opposition To Senate Bill

A second union representing immigration enforcement officers has expressed opposition to the Senate version of comprehensive immigration reform legislation, arguing that the bill fails to address the "insurmountable bureaucracy" at the agency that oversees lawful immigration to the U.S.